Clinical carbapenem-resistant Klebsiella pneumoniae isolates simultaneously harboring bla NDM-1, bla OXA types and qnrS genes from the Kingdom of Bahrain: Resistance profile and genetic environment
暂无分享,去创建一个
K. Tabbara | N. Saeed | Nayeem Ahmad | K. Bindayna | M. Shahid | R. M. Joji | F. Dar | Ali E Al-Mahmeed | Mohd. Shadab
[1] Nessma Hessin Mohamed Gandor,et al. Characterization of Carbapenem-Resistant K. Pneumoniae Isolated from Intensive Care Units of Zagazig University Hospitals , 2022, Antibiotics.
[2] J. Tanne. Covid-19: Antimicrobial resistance rose dangerously in US during pandemic, CDC says , 2022, BMJ.
[3] Samira Choudhury,et al. Antimicrobial resistance and the COVID-19 pandemic , 2022, Bulletin of the World Health Organization.
[4] M. Reis,et al. Prolonged Outbreak of Carbapenem and Colistin-Resistant Klebsiella pneumoniae at a Large Tertiary Hospital in Brazil , 2022, Frontiers in Microbiology.
[5] T. Banerjee,et al. Extensive outbreak of colistin resistant, carbapenemase (blaOXA-48, blaNDM) producing Klebsiella pneumoniae in a large tertiary care hospital, India , 2022, Antimicrobial resistance and infection control.
[6] F. Kolaylı,et al. Molecular characterization of carbapenemase producing Klebsiella pneumoniae strains by multiplex PCR and PFGE methods: The first K.pneumoniae isolates co-producing OXA-48/KPC and KPC/NDM in Turkey. , 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[7] J. Rolain,et al. Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing Enterobacteriaceae Isolated from the Mohamed VI University Hospital in Marrakech, Morocco , 2021, Antibiotics.
[8] A. Ardebili,et al. Molecular characteristics of antibiotic-resistant Escherichia coli and Klebsiella pneumoniae strains isolated from hospitalized patients in Tehran, Iran , 2020, Annals of clinical microbiology and antimicrobials.
[9] S. Koo,et al. Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates , 2020, Journal of clinical laboratory analysis.
[10] M. Castanheira,et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018. , 2020, Microbial drug resistance.
[11] P. Aris,et al. Molecular mechanisms and prevalence of colistin resistance of Klebsiella pneumoniae in the Middle East region: A review over five last years. , 2020, Journal of global antimicrobial resistance.
[12] M. Shohayeb,et al. The First Egyptian Report Showing the Co-Existence of blaNDM-25, blaOXA-23, blaOXA-181, and blaGES-1 Among Carbapenem-Resistant K. pneumoniae Clinical Isolates Genotyped by BOX-PCR , 2020, Infection and drug resistance.
[13] O. Orole,et al. Characterization and Plasmid Profile of Resistant Klebsiella pneumoniae Isolates in Patients with Urinary Tract Infection in Nasarawa State, Nigeria , 2020 .
[14] K. Bush,et al. Epidemiology of β-Lactamase-Producing Pathogens , 2020, Clinical Microbiology Reviews.
[15] A. A. Elshamy,et al. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options , 2020, Future science OA.
[16] M. Beatty,et al. Outbreak of colistin-resistant organisms at a tertiary hospital in Riyadh, Saudi Arabia, 2016 , 2019, The Pan African medical journal.
[17] G. Peirano,et al. The Global Ascendency of OXA-48-Type Carbapenemases , 2019, Clinical Microbiology Reviews.
[18] B. Berglund. Acquired Resistance to Colistin via Chromosomal And Plasmid-Mediated Mechanisms in Klebsiella pneumoniae , 2019, Infectious Microbes and Diseases.
[19] J. Ahmad,et al. Enterobacterial infection in Saudi Arabia: First record of Klebsiella pneumoniae with triple carbapenemase genes resistance. , 2019, Journal of infection in developing countries.
[20] Mohammed A. Al-Biltagi,et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in a Tertiary Care Center in the Kingdom of Bahrain , 2019, Journal of laboratory physicians.
[21] F. Hu,et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.
[22] Rong Zhang,et al. Tracking microevolution events among ST11 carbapenemase-producing hypervirulent Klebsiella pneumoniae outbreak strains , 2018, Emerging Microbes & Infections.
[23] Hongwei Zhou,et al. Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract , 2018, Emerging Microbes & Infections.
[24] J. Lavigne,et al. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[25] Asad U. Khan,et al. Occurrence of blaNDM Variants Among Enterobacteriaceae From a Neonatal Intensive Care Unit in a Northern India Hospital , 2018, Front. Microbiol..
[26] E. Burd,et al. Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection , 2018, mBio.
[27] I. Al-Zahrani,et al. The emergence of carbapenem-resistant Klebsiella pneumoniae isolates producing OXA-48 and NDM in the Southern (Asir) province, Saudi Arabia , 2018, Saudi medical journal.
[28] M. A. El-Feky,et al. Co-occurrence of Plasmid-mediated Quinolone Resistance and Carbapenemases in Klebsiella pneumoniae Isolates in Assiut, Egypt , 2017 .
[29] M. Bonilla,et al. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[30] D. van Duin,et al. The global epidemiology of carbapenemase-producing Enterobacteriaceae , 2017, Virulence.
[31] Asad U. Khan,et al. Structure, Genetics and Worldwide Spread of New Delhi Metallo-β-lactamase (NDM): a threat to public health , 2017, BMC Microbiology.
[32] Robert A. Weinstein,et al. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.
[33] Christina A. Sutherland,et al. Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. , 2017, Journal of thoracic disease.
[34] S. Richter,et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] Min-Jeong Park,et al. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea , 2016, Annals of laboratory medicine.
[36] Ronald N. Jones,et al. Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015 , 2016, Antimicrobial Agents and Chemotherapy.
[37] K. Kazmierczak,et al. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam , 2016, Antimicrobial Agents and Chemotherapy.
[38] Y. Carmeli,et al. The negative impact of antibiotic resistance. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[39] M. Albert,et al. High Prevalence of New Delhi Metallo-β-Lactamase-1 (NDM-1) Producers among Carbapenem-Resistant Enterobacteriaceae in Kuwait , 2016, PloS one.
[40] H. Zhang,et al. Outbreak of NDM-1-producing Klebsiella pneumoniae ST76 and ST37 isolates in neonates , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[41] K. Bush. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. , 2015, International journal of antimicrobial agents.
[42] P. Nordmann,et al. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance , 2015, Antimicrobial Agents and Chemotherapy.
[43] Christina A. Sutherland,et al. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. , 2015, Clinical therapeutics.
[44] V. Rotimi,et al. Characterization of Carbapenem-Resistant Enterobacteriaceae with High Rate of Autochthonous Transmission in the Arabian Peninsula , 2015, PloS one.
[45] F. Amer,et al. Occurrence of classes I and II integrons in Enterobacteriaceae collected from Zagazig University Hospitals, Egypt , 2015, Front. Microbiol..
[46] R. Valaperta,et al. Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division , 2015, BioMed research international.
[47] D. Hoban,et al. In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012. , 2014, Journal of global antimicrobial resistance.
[48] Tyson A. Clark,et al. Whole-Genome Assembly of Klebsiella pneumoniae Coproducing NDM-1 and OXA-232 Carbapenemases Using Single-Molecule, Real-Time Sequencing , 2014, Antimicrobial Agents and Chemotherapy.
[49] Ronald N. Jones,et al. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). , 2014, International journal of antimicrobial agents.
[50] Ronald N. Jones,et al. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). , 2014, The Journal of antimicrobial chemotherapy.
[51] Kui Zhang,et al. Molecular characterization of clinical multidrug-resistant Klebsiella pneumoniae isolates , 2014, Annals of Clinical Microbiology and Antimicrobials.
[52] Y. Yu,et al. First description of NDM-1-, KPC-2-, VIM-2- and IMP-4-producing Klebsiella pneumoniae strains in a single Chinese teaching hospital , 2014, Epidemiology and Infection.
[53] J. Karlowsky,et al. Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections , 2014, Core evidence.
[54] Z. Memish,et al. The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[55] Yongfei Hu,et al. Structural Diversity of Class 1 Integrons and Their Associated Gene Cassettes in Klebsiella pneumoniae Isolates from a Hospital in China , 2013, PloS one.
[56] R. Jureen,et al. Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[57] D. Paterson,et al. β-Lactamase Production in Key Gram-Negative Pathogen Isolates from the Arabian Peninsula , 2013, Clinical Microbiology Reviews.
[58] Xiaojiao Zhang,et al. Prevalence of Plasmid-Mediated Quinolone Resistance and Aminoglycoside Resistance Determinants among Carbapeneme Non-Susceptible Enterobacter cloacae , 2012, PloS one.
[59] Herman Goossens,et al. Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action , 2012, Antimicrobial Resistance and Infection Control.
[60] P. Nordmann,et al. Emergence of OXA-48-Type Carbapenemase-Producing Enterobacteriaceae in German Hospitals , 2012, Antimicrobial Agents and Chemotherapy.
[61] P. Nordmann,et al. Association of the Emerging Carbapenemase NDM-1 with a Bleomycin Resistance Protein in Enterobacteriaceae and Acinetobacter baumannii , 2012, Antimicrobial Agents and Chemotherapy.
[62] P. Nordmann,et al. Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco. , 2011, The Journal of antimicrobial chemotherapy.
[63] P. Nordmann,et al. Genetic Features of blaNDM-1-Positive Enterobacteriaceae , 2011, Antimicrobial Agents and Chemotherapy.
[64] Timothy R. Walsh,et al. Characterization of a New Metallo-β-Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India , 2009, Antimicrobial Agents and Chemotherapy.
[65] G. Araj,et al. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. , 2008, Diagnostic microbiology and infectious disease.
[67] A. Shibl,et al. Characterization of carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in carbapenem-insensitive Escherichia coli and Klebsiella pneumoniae in Riyadh hospitals. , 2018, Journal of infection and public health.
[68] Y. Çetinkol,et al. The investigation of oxacillinase/metallo-beta-lactamase genes and clonal analysis in carbapenem-resistant Klebsiella pneumoniae. , 2016, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.